Sub Q Maintenance Success Set To Improve Entyvio's Position In Ulcerative Colitis
New positive data with more convenient formulation set stage for increased Entyvio competitiveness in ulcerative colitis maintenance setting, while other early results bode well for Ninlaro in maintenance use in multiple myeloma.
You may also be interested in...
Keeping Track: US FDA Approves Pfizer’s Vyndaqel, Jacobus’ Ruzurgi, But Nixes Acacia’s Barhemsys Again
The latest drug development news and highlights from our US FDA Performance Tracker.
Takeda's Ninlaro seems to have proved its mettle in the first major placebo-controlled trial assessing a proteasome inhibitor as a single-agent maintenance therapy in multiple myeloma.
Takeda may have to shed a Shire late-stage pipeline asset to meet European anti-competition concerns around the companies' planned merger, although the process is not expected to derail the deal's timing.